Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

This Clinical Brief is supported by Boehringer Ingelheim.

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil^® 2, the first trial to study subcutaneous Spevigo^® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.